Green Brook, NJ, United States of America

Rongze Kuang

This inventor holds 24 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 22 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Merck Sharp + Dohme Corp., Schering Corporation, Albany Molecular Research, Inc.. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rongze Kuang. Retrieved from https://idiyas.com/inventor/rongze-kuang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 7)

% Patents Active = 75.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 22 (Patent Applications = 18)

Average Co-Inventor Count = 13.5

ph-index = 3

Forward Citations = 39(Granted Patents)

Company Filing History:

21 out of 2,405

Merck Sharp + Dohme Corp.

Albany Molecular Research, Inc.

patents

4. 1 out of 67

Merck Sharp & Dohme LLC

patents

where one patent can have more than one assignee

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

Plasma Kallikrein Inhibitors

Factor XI Inhibitors

Adenosine Receptor Antagonists

Biaryl-Spiroaminooxazoline

A2A Antagonist Properties

PDE4 Inhibitors

Aminopyrazine Compounds

Glucan Synthase Inhibitors

Triazolopyrimidine Compounds

Diacylglycerol Acyltransferase Inhibitors

Heterobicyclo-Substituted Compounds

Substituted Quinazoline Compounds

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12528786 - Plasma kallikrein inhibitors (2026-01-20),

2. 12466831 - Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use (2025-11-11),

3. 12459927 - Plasma kallikrein inhibitors (2025-11-04),

4. 12428397 - Factor XI activation inhibitors (2025-09-30),

5. 12414952 - Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use (2025-09-16),

6. 12304899 - Factor XI activation inhibitors (2025-05-20),

7. 11046714 - 2,2-difluorodioxolo Areceptor antagonists (2021-06-29),

8. 10822338 - Substituted aminoquinazoline compounds as Aantagonist (2020-11-03),

9. 10472347 - Aminopyrazine compounds with A2A antagonist properties (2019-11-12),

10. 10143681 - Factor XIa inhibitors (2018-12-04),

11. 10138212 - [object Object] (2018-11-27),

12. 10081617 - Factor XIa inhibitors (2018-09-25),

13. 10011615 - Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties (2018-07-03),

14. 10011585 - Factor XIa inhibitors (2018-07-03),

15. 9868727 - Factor XIa inhibitors (2018-01-16),

Title: The Innovative Journey of Rongze Kuang

Introduction

Rongze Kuang, based in Green Brook, NJ, has made significant contributions to the field of pharmaceuticals and medicinal chemistry. With an impressive portfolio of 19 patents, his work focuses on developing innovative solutions for various medical challenges, including thromboses and neurological disorders.

Latest Patents

Among his notable patents, Rongze has recently developed selective Factor XI activation inhibitors, which offers a promising approach in treating or preventing thromboses, embolisms, hypercoagulability, and fibrotic changes. His compounds, outlined in the patent, are designed to effectively manage conditions related to abnormal blood coagulation.

Additionally, he has patented 2,2-difluorodioxolo compounds that act as antagonists of Areceptor. This invention is particularly relevant for addressing neurological disorders and diseases linked to Areceptor dysfunction. The pharmaceutical compositions derived from these compounds hold potential for both treatment and prevention of such conditions.

Career Highlights

Rongze Kuang has built a robust career working with renowned pharmaceutical companies. Notably, he has been associated with Merck Sharp & Dohme Corporation and Schering Corporation. His experience in these institutions has contributed greatly to his innovative capabilities and patent portfolio.

Collaborations

Throughout his career, Rongze has collaborated with esteemed colleagues, including Pauline C. Ting and Heping Wu. These partnerships have fostered an environment of creativity and shared knowledge, leading to the advancement of various pharmaceutical innovations.

Conclusion

With 19 patents to his name and a strong background in pharmaceutical research, Rongze Kuang stands out as a notable inventor in the field. His work on Factor XI activation inhibitors and Areceptor antagonists not only showcases his innovative mindset but also holds promise for future medical advancements.

Profile summary based on public USPTO records.